Affordable Access

Access to the full text

Real-World Use Of Ultrathin-Strut Biodegradable Polymer–Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes

Authors
  • Ajmera, Prakash1
  • Pothineni, Ramesh2
  • Chawla, Kamal Kumar1
  • Mantravadi, Sai Sudhakar3
  • Jariwala, Pankaj Vinod4
  • Vijan, Vinod5
  • Vijan, Vikrant5
  • 1 Department of Cardiology, Malla Reddy Narayana Multispeciality Hospital, Hyderabad, Telangana 500055 , (India)
  • 2 Department of Cardiology, Ramesh Hospitals, Vijayawada, Andhra Pradesh, 520008 , (India)
  • 3 Department of Cardiology, Gleneagles Global Hospital, Hyderabad, Telangana, 500004 , (India)
  • 4 Department of Cardiology, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, 500082 , (India)
  • 5 Department of Cardiology, Vijan Cardiac and Critical Care Centre, Nashik, Maharashtra, 422005 , (India)
Type
Published Article
Journal
Vascular Health and Risk Management
Publisher
Dove Medical Press
Publication Date
Oct 18, 2019
Volume
15
Pages
439–447
Identifiers
DOI: 10.2147/VHRM.S200699
PMID: 31695399
PMCID: PMC6805243
Source
PubMed Central
Keywords
License
Green

Abstract

Background Although a number of drug-eluting stents have been developed with different design, composition, and polymers, the search for an ideal drug-eluting stent is ongoing. The Tetriflex (Sahajanand Medical Technology, Surat, India) is a newer-generation, ultrathin (60 µm) biodegradable polymer–coated sirolimus-eluting stent (SES) designed with a unique long dual Z-link on a cobalt–chromium alloy. The present registry aimed to evaluate the safety and clinical outcomes of the Tetriflex SES at 6-month post-implantation. Methods This was an investigator-initiated, retrospective, multicenter, single-arm, observational registry conducted at five tertiary-care centers in India. A total of 1,269 consecutive patients with coronary artery disease who underwent implantation of at least one Tetriflex SES between March 2017 and March 2018 were included. The primary outcome was considered a composite of cardiac death, myocardial infarction and target-lesion revascularization (TLR) at 6-month follow-up. Stent thrombosis was evaluated as a safety outcome at 6-month follow-up. Results The mean age of patients was 54.99±10.80 years. Among 1,515 lesions treated with 1,682 Tetriflex SES, 58.3% were type C lesions. Six-month follow-up was done for 1,245 of 1,269 (98.1%) patients. At 6 months, composite events had occurred in 31 (2.5%) patients, consisting of ten (0.8%) cardiac deaths, 16 (1.3%) myocardial infarctions, and five (0.4%) TLRs. Stent thrombosis was observed in seven (0.56%) cases at 6 months. A subgroup analysis between diabetic and nondiabetic patients did not reveal any statistically significant difference for clinical outcomes at 6-month follow-up. Conclusion The results of the current registry outline the safety and effectiveness of the Tetriflex SES in real-world patients, as it displayed favorable clinical outcomes at 6-month follow-up, with low incidence of TLR and stent thrombosis.

Report this publication

Statistics

Seen <100 times